Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Assets (2016 - 2025)

Historic Assets for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $504.6 million.

  • Spyre Therapeutics' Assets rose 1983.31% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.6 million, marking a year-over-year increase of 1983.31%. This contributed to the annual value of $608.5 million for FY2024, which is 7799.27% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Assets stood at $504.6 million, which was up 1983.31% from $538.8 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Assets peaked at $608.5 million during Q4 2024, and registered a low of $52.5 million during Q1 2023.
  • Its 5-year average for Assets is $279.7 million, with a median of $207.3 million in 2023.
  • Per our database at Business Quant, Spyre Therapeutics' Assets tumbled by 4916.69% in 2022 and then skyrocketed by 82959.79% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Assets stood at $109.9 million in 2021, then tumbled by 35.28% to $71.1 million in 2022, then skyrocketed by 380.52% to $341.9 million in 2023, then soared by 77.99% to $608.5 million in 2024, then decreased by 17.07% to $504.6 million in 2025.
  • Its Assets stands at $504.6 million for Q3 2025, versus $538.8 million for Q2 2025 and $569.8 million for Q1 2025.